Douglas B. Snyder Form 3 GW PHARMACEUTICALS / Douglas B. Snyder ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Snyder Douglas B.

(Last) (First) (Middle)

SOVEREIGN HOUSE, VISION PARK, HISTON

(Street)

CAMBRIDGE X0 CB24 9BZ

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/01/2018

3. Issuer Name and Ticker or Trading Symbol
GW PHARMACEUTICALS PLC [ GWPH ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Legal Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options(1)	08/10/2019	03/15/2020	Ordinary Shares	9,180	0.0013(2)	D
Stock Options(1)	08/10/2020	03/15/2021	Ordinary Shares	9,180	0.0013(2)	D
Stock Options(1)	08/10/2021	03/15/2022	Ordinary Shares	9,180	0.0013(2)	D
Stock Options(1)	08/10/2020	03/15/2021	Ordinary Shares	122,364	0.0013(2)	D
Stock Options(1)(3)	08/10/2020	08/10/2027	Ordinary Shares	82,956	9.8117	D
Stock Options(1)	02/26/2019	03/15/2020	Ordinary Shares	9,612	0.0013(2)	D
Stock Options(1)	02/26/2020	03/15/2021	Ordinary Shares	9,612	0.0013(2)	D
Stock Options(1)	02/26/2021	03/15/2022	Ordinary Shares	9,612	0.0013(2)	D
Stock Options(1)	02/26/2022	03/15/2023	Ordinary Shares	9,612	0.0013(2)	D
Stock Options(1)	02/26/2021	03/15/2022	Ordinary Shares	128,712	0.0013(2)	D
Stock Options(1)(3)	02/26/2021	02/26/2028	Ordinary Shares	63,252	9.6092	D

Explanation of Responses:

1. Granted pursuant to the Issuer's Long-Term Incentive Plan.

2. Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.302 U.S. Dollars as of September 28, 2018.

3. The reported options are options to purchase American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer.

Remarks:

	/s/ Douglas B. Snyder	10/01/2018
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.